Heterogeneity in response to treatment with buthionine sulfoximine or interferon in human malignant glioma cells.
Two tumor cell lines were established from each of three human malignant glioma biopsy specimens (M059, M067, M071) and sensitivity to treatment with radiation or chemotherapeutic agents (BCNU, nitrogen mustard) was determined. The effects of recombinant human interferon-alpha (rIFN) on the radiation response and of buthionine sulfoximine (BSO) on the drug response were investigated as well. For tumor M059, two cell lines that differed significantly in radiosensitivity were isolated (surviving fractions at 2 Gy = 0.02 and 0.64). The chemosensitivity and response to chemical modification differed as well. Cell lines established from tumor M071 differed in their response to rIFN only and were not sensitized by BSO. M067 cell lines showed little difference and were not sensitized by either agent. These results suggest that differences may exist both within and among human malignant gliomas with regard to their sensitivity to drugs, radiation, and the ability of chemical agents to modify treatment responses.
Allalunis-Turner
M J
MJ
Cross Cancer Institute, Edmonton, Alberta, Canada.
Barron
G M
GM
Day
R S
RS
Dobler
K
K
Urtasun
R C
RC
D019328:Buthionine Sulfoximine; D002330:Carmustine / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D016898:Interferon-alpha / Q000494:pharmacology*; D008466:Mechlorethamine / Q000494:pharmacology; D008717:Methionine Sulfoximine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects
D016898:Interferon-alpha; D011994:Recombinant Proteins; D008717:Methionine Sulfoximine; D019328:Buthionine Sulfoximine; D008466:Mechlorethamine; D002330:Carmustine